TGFB1 and breast carcinoma: One study found that delivering TGF-β inhibitors and selenocysteine to breast cancer cells can reduce TGF-β in the TME, improve NK cell activity, and increase antitumor capability, suggesting that NK-targeted immunotherapies may be promising [95].